DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744. doi: 10.1002/acn3.51408. Epub 2021 Jul 7.

Abstract

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18-0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / pharmacology*
  • COVID-19 / epidemiology
  • COVID-19 / physiopathology*
  • Female
  • France / epidemiology
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / pharmacology*
  • Interferons / adverse effects
  • Interferons / pharmacology*
  • Italy / epidemiology
  • Male
  • Meta-Analysis as Topic
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / epidemiology
  • Multivariate Analysis
  • Protective Factors
  • Retrospective Studies
  • Risk Factors
  • Rituximab / adverse effects
  • Rituximab / pharmacology*
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Rituximab
  • Interferons
  • ocrelizumab